🔎 By pooling data from DRUP-like pragmatic trials across countries, PRIME-ROSE enables faster cohort completion for rare molecular alterations — cohorts that would otherwise remain too small at a national level. Through aligned study designs, harmonized endpoints, and OMOP-based data standardization, we create a shared framework for robust cross-country analyses.

Patients with rare genomic alterations often face limited treatment options and fragmented evidence. Through structured data sharing, OMOP-based harmonization, and aligned statistical analysis plans, PRIME-ROSE enables faster cohort completion and more robust clinical insights across Europe.

Since the launch, PRIME-ROSE has pooled data from 1,000+ patients across 300+ cohorts — demonstrating that collaboration is not just beneficial, but essential,to move the field forward.

🔗Read the full article ‘Crossing  borders’   in   data  standardisation: application  of   OMOP   CDM  in   an   international clinical trial network inprecision cancer medicine